Brain Neoplasms: Clinical Trials

399 trials for Brain Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

399 completed. 399 Phase 2, 86 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2399Completed 399
Phase 186Completed 86
Phase 37Completed 7

Follow Brain Neoplasms: new trials by email Literature Review of Brain Neoplasms trials Research Report on Brain Neoplasms

Trials (filtered) newest first · largest first

All 399 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2CompletedReveal Pharmaceuticals Inc.182024-08-152025-12-26
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma
Phase 2CompletedVirginia Commonwealth University702024-07-082025-10-01
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
Patritumab deruxtecan - Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
Phase 2CompletedMedSIR632023-11-242026-05-04
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab
Phase 2 / Phase 3CompletedSun Yat-sen University402023-05-142024-11-13
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
Best Practice, Neuropsychological Assessment, Quality-of-Life Assessment - Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Phase 2CompletedOhio State University Comprehensive Cancer Center1102022-08-302026-10-21
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Furmonertinib 160 mg, Q.D. - Furmonertinib, EGFR-mutation
Phase 2CompletedPeking Union Medical College242022-07-112025-12-19
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
TY-9591 Tablets - NSCLC, EGFR Activating Mutation
Phase 2CompletedTYK Medicines, Inc292022-04-022024-12-30
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
TMZ, ipilimumab 3mg/kg, Nivolumab - Glioblastoma, Gliosarcoma
Phase 2CompletedNational Cancer Institute (NCI)472021-12-082026-04-17
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor
Phase 2CompletedJohn Yu502021-09-302026-07-10
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
Dendritic cell vaccination + temozolomide-based chemoradiation, Dendritic cell vaccination +- conventional next-line treatment - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 1 / Phase 2CompletedUniversity Hospital, Antwerp102021-09-102026-06-05
MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer
Unity-based MR-Linac guided FSRT - Non-small Cell Lung Cancer
Phase 2CompletedSun Yat-sen University552021-06-012024-12-12
Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
Pico G2 4K Headset with Applied VR software, Patient Reported Questionnaires, Saliva sample collection (hormones) - Anxiety
Phase 2CompletedNational Cancer Institute (NCI)612021-03-182026-03-11
Preoperative Stereotactic Radiosurgery for Brain Metastases
Preoperative SRS - Brain Metastases
Phase 2CompletedCentre Jean Perrin702021-02-042026-11-20
Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation
Alcon - Intracranial Tumor
Phase 2CompletedTechnical University of Munich2102020-12-302022-11-10
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor
Phase 1 / Phase 2CompletedEli Lilly and Company472020-11-092026-03-02
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
lerapolturev, pembrolizumab - Glioblastoma, Recurrent Glioblastoma
Phase 2CompletedIstari Oncology, Inc.252020-10-212025-06-05
Keynatinib in Treated Patients With NSCLC and Brain Metastases
Keynatinib - Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases
Phase 2CompletedMedolution Ltd.162020-10-212025-01-22
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
5-Aminolevulinic Acid Hydrochloride, Oral - Brain Tumor, Pediatric
Phase 2CompletedUniversität Münster782020-09-252025-12-10
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
Tislelizumab, Carboplatin, Pemetrexed - NSCLC Stage IV, Brain Metastases
Phase 2CompletedSun Yat-sen University362020-09-152023-05-25
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
18F fluciclovine - Brain Metastases
Phase 2CompletedBlue Earth Diagnostics232020-08-312025-07-20

Showing 20 of 399. Sign in to see all of them.

Narrower conditions

Glioblastoma (191)  ·  Gliosarcoma (123)  ·  Glioma (119)  ·  Central Nervous System Neoplasms (109)  ·  Astrocytoma (102)  ·  Oligodendroglioma (80)  ·  Breast Neoplasms (29)  ·  Ependymoma (29)  ·  Neoplasm Metastasis (28)  ·  Carcinoma, Non-Small-Cell Lung (27)  ·  Medulloblastoma (24)  ·  Neoplasms (23)  ·  Meningioma (22)  ·  Melanoma (21)

Broader conditions

Neoplasms by Site (397)  ·  Brain Diseases (395)  ·  Nervous System Neoplasms (395)  ·  Central Nervous System Diseases (394)  ·  Nervous System Diseases (394)  ·  Neoplasms (376)  ·  Central Nervous System Neoplasms (290)  ·  Neoplasms by Histologic Type (290)  ·  Neoplasms, Nerve Tissue (278)  ·  Neuroectodermal Tumors (271)  ·  Neoplasms, Germ Cell and Embryonal (270)  ·  Neoplasms, Glandular and Epithelial (265)  ·  Neoplasms, Neuroepithelial (253)  ·  Glioma (132)  ·  Astrocytoma (111)

Interventions

Temozolomide (62)  ·  Bevacizumab (49)  ·  Radiotherapy (30)  ·  Irinotecan (22)  ·  Carboplatin (17)  ·  Carmustine (11)  ·  Cisplatin (11)  ·  Cyclophosphamide (11)  ·  Erlotinib Hydrochloride (11)  ·  Etoposide (10)  ·  Lapatinib (10)  ·  Radiosurgery (10)  ·  Filgrastim (9)  ·  Sirolimus (8)  ·  Sorafenib (8)

Sponsors

National Cancer Institute (NCI) (51)  ·  Duke University (30)  ·  M.D. Anderson Cancer Center (15)  ·  Memorial Sloan Kettering Cancer Center (12)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (12)  ·  New Approaches to Brain Tumor Therapy Consortium (9)  ·  Novartis Pharmaceuticals (9)  ·  Children's Oncology Group (7)  ·  European Organisation for Research and Treatment of Cancer - EORTC (6)  ·  Wake Forest University Health Sciences (6)  ·  Radiation Therapy Oncology Group (5)  ·  Alliance for Clinical Trials in Oncology (4)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  Case Comprehensive Cancer Center (4)  ·  Jonsson Comprehensive Cancer Center (4)

Countries

United States (308)  ·  Canada (43)  ·  France (35)  ·  Australia (21)  ·  Spain (21)  ·  Germany (20)  ·  Italy (19)  ·  Switzerland (19)  ·  Netherlands (18)  ·  China (16)  ·  United Kingdom (15)  ·  Belgium (14)  ·  Austria (10)  ·  Israel (8)  ·  Puerto Rico (8)

Top investigators

Henry S. Friedman, MD (9)  ·  David A. Reardon, MD (6)  ·  Edward G. Shaw, MD (4)  ·  Evanthia Galanis (4)  ·  Lauren E. Abrey, MD (4)  ·  Annick Desjardins, MD, FRCPC (3)  ·  Betty Lawrence (3)  ·  Darell D. Bigner, MD, PhD (3)  ·  David Peereboom, MD (3)  ·  Evanthia Galanis, MD (3)  ·  Howard A. Fine, MD (3)  ·  James J. Vredenburgh, MD (3)  ·  Stanislaw R. Burzynski, MD, PhD (3)

Results publications

PMID 25098701, PMID 11772431, PMID 11907388, PMID 1408229, PMID 14586216, PMID 14625709, PMID 14670747, PMID 14769136, PMID 14769138, PMID 14769140, PMID 15073861, PMID 15292713, PMID 15514370, PMID 15758009, PMID 16012795, PMID 16034522, PMID 16133802, PMID 16170172, PMID 16314647, PMID 16533878, PMID 16549835, PMID 16817692, PMID 16863926, PMID 16877733, PMID 16890064, PMID 16914578, PMID 17031561, PMID 17317837, PMID 17418968, PMID 17470857, PMID 17610262, PMID 17987262, PMID 18094423, PMID 18182667, PMID 18215105, PMID 18623206, PMID 18661102, PMID 18824712, PMID 18850068, PMID 18981004, PMID 18981465, PMID 18989154, PMID 19066728, PMID 19188181, PMID 19204207, PMID 19262392, PMID 19562254, PMID 19720927, PMID 19920819, PMID 20143438

NIH funding

U01CA062399 (8), 2014 (6), U10CA025224 (6), U10CA021661 (5), U01CA062475 (4), U01CA137443 (4), 2017 (3), P30CA008748 (3), U10CA098543 (3), U10CA180868 (3), 2009 (2), 2015 (2), 2019 (2), 2023 (2), P30CA015704 (2)